Clinical Trial Update: Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib (Velcade) given after allogeneic peripheral blood stem cell transplantation in patients with multiple myeloma to assess safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED